268 related articles for article (PubMed ID: 34359872)
1. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia.
da Silva RF; Petta CA; Derchain SF; Alici E; Guimarães F
Hum Immunol; 2014 Aug; 75(8):777-84. PubMed ID: 24882570
[TBL] [Abstract][Full Text] [Related]
5. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
7. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells.
Quatrini L; Vacca P; Tumino N; Besi F; Di Pace AL; Scordamaglia F; Martini S; Munari E; Mingari MC; Ugolini S; Moretta L
J Allergy Clin Immunol; 2021 Jan; 147(1):349-360. PubMed ID: 32417134
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
10. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
14. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
Liu M; Xie J; Zhao S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
17. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
[TBL] [Abstract][Full Text] [Related]
18. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
19. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
20. Positive psychosocial factors and NKT cells in ovarian cancer patients.
Lamkin DM; Lutgendorf SK; McGinn S; Dao M; Maiseri H; DeGeest K; Sood AK; Lubaroff DM
Brain Behav Immun; 2008 Jan; 22(1):65-73. PubMed ID: 17643954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]